Under Construction

2016 Selected Research on Lung Cancer

Autoantibodies against tumor-associated antigens in the early detection of lung cancer

L Dai, JCJ Tsay, J Li, TA Yie, JS Munger, H Pass… – Lung Cancer, 2016
Objectives Autoantibodies against tumor-associated antigens (TAAs) identified in patients
with advanced lung cancer may be detected in subjects with early lung cancer or even
predate the diagnosis. The purpose of this study is to address the temporal relationship


O 6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?

BI Hiddinga, P Pauwels, A Janssens… – Lung Cancer, 2016
Abstract This manuscript addresses the role of O 6-methylguanine-DNA methyltransferase
(MGMT) as a biomarker in the oncogenesis of cancer and the opportunity of turning this
gene into a drugable target in neuroendocrine tumours of the lung. Studies in brain

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis

D De Ruysscher, B Lueza, C Le Péchoux, DH Johnson… – Annals of Oncology, 2016
Results Twelve trials with 2,668 patients were eligible. Data from nine trials comprising 2,305
patients were available for analysis. The median follow-up was 10 years. When all trials were
analysed together, “earlier or shorter” vs. “later or longer” thoracic radiotherapy did not

… Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With …

L Crinò, MJ Ahn, F De Marinis, HJM Groen, H Wakelee… – Journal of Clinical Oncology, 2016
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-
rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and
with or without prior therapy with an inhibitor of the ALK protein. Data are presented from a

Molecular Mechanisms of Resistance to First-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner… – Cancer Discovery, 2016
Abstract Advanced, anaplastic lymphoma kinase (ALK)-positive lung cancer is currently
treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-
generation ALK inhibitors (eg, ceritinib, alectinib) upon progression. Second-generation

Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress.

H Saijo, Y Hirohashi, T Torigoe, R Horibe, A Takaya… – Oncotarget, 2016
Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are reasonable targets for
cancer therapy. However, recent studies have revealed that some non-CSCs/CICs have
plastic ability and can dedifferentiate into CSCs/CICs. Therefore, an understanding of the

… blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression …

YOH Kiyotaka, Y HOSOMI, K KASAHARA, K YAMADA… – Lung Cancer, 2016
Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II,
double-blind, randomized, placebo-controlled study assessed efficacy and safety of

Role of TGF-β-induced Claudin-4 expression through c-Jun signaling in non-small cell lung cancer

G Rachakonda, T Vu, L Jin, D Samanta, PK Datta – Cellular Signalling, 2016
Abstract Claudin-4 has been identified as an integral member of tight junctions and has
been found to be upregulated in various types of cancers especially in metastatic cancers.
However, the molecular mechanism of the upregulation of Claudin-4 and its role in lung

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

R Rosell, N Karachaliou – 2016
Knowledge of cancer genome landscapes has improved tremendously through application
of next-generation sequencing technologies 1, 2; however, genomic analysis frequently
focuses on the static view of the primary tumor genome at the time of diagnosis and,

The Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

F Dammeijer, LA Lievense, GDM Veerman… – Journal of Clinical Oncology, 2016
Purpose Programmed cell death protein-1-checkpoint blockers have recently been
approved as second-line treatment for advanced non–small-cell lung cancer (NSCLC).
Unfortunately, only a subgroup of patients responds and shows long-term survival to these